A Vital Sign-based Prediction Algorithm for Differentiating COVID-19 Versus Seasonal
Influenza in Hospitalized Patients

Naveena Yanamala*[1,2], Nanda H. Krishna[1,2], Quincy A. Hathaway[1], Aditya Radhakrishnan[1,2],
Srinidhi Sunkara[1, 2], Heenaben Patel[1], Peter Farjo[1], Brijesh Patel[1], Partho P Sengupta*[1].

Author Affiliations: [1]Division of Cardiology, West Virginia University Medicine Heart &
Vascular Institute, Morgantown, WV**;** [2]Institute for Software Research, School of Computer
Science, Carnegie Mellon University, Pittsburgh, PA

Address of Correspondence:
9

*Partho P. Sengupta, MD, DM
Heart & Vascular Institute
West Virginia University
1 Medical Center Drive,
Morgantown, WV 26506
E-Mail: Partho.Sengupta@wvumedicine.org
Twitter: @ppsengupta1

*Naveena Yanamala, MS, PhD
Heart & Vascular Institute
West Virginia University
1 Medical Center Drive,
Morgantown, WV 26506
E-Mail: naveena.yanamala.m@wvumedicine.org
Twitter: @YanamalaNaveena

Abstract

Patients with influenza and SARS-CoV2/Coronavirus disease 2019 (COVID-19) infections have
different clinical course and outcomes. We developed and validated a supervised machine
learning pipeline to distinguish the two viral infections using the available vital signs and
demographic dataset from the first hospital/emergency room encounters of 3,883 patients who
had confirmed diagnoses of influenza A/B, COVID-19 or negative laboratory test results. The
models were able to achieve an area under the receiver operating characteristic curve (ROC
AUC) of at least 97% using our multiclass classifier. The predictive models were externally
validated on 15,697 encounters in 3,125 patients available on TrinetX database that contains
patient-level data from different healthcare organizations. The influenza vs. COVID-19-positive
model had an AUC of 98%, and 92% on the internal and external test sets, respectively. Our
study illustrates the potentials of machine-learning models for accurately distinguishing the two
viral infections. The code is made available at https://github.com/ynaveena/COVID-19-vs-
Influenza and may be have utility as a frontline diagnostic tool to aid healthcare workers in
triaging patients once the two viral infections start cocirculating in the communities.
26
27 **Keywords:** Seasonal Influenza, Machine learning, Extreme gradient boosting trees.

28
29

30 **Word count (main text):** 3,437 (Limit 3,500); **Word count (methods):** 1,630 (Limit 3,000)

Main

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV 2) causing coronavirus disease 2019 (COVID-19) has led to an unprecedented global crisis due to its vigorous transmission, spectrum of respiratory manifestations, and vascular affects [1-3]. The etiology of the disease is further complicated by a diverse set of clinical presentations, ranging from asymptomatic to progressive viral pneumonia and mortality [4]. Due to its similar symptomatology, COVID-19 has drawn comparisons to the seasonal influenza epidemic.[5] Both infections commonly present with overlapping symptoms, leading to a clinical dilemma for clinicians as SARS-CoV 2 carries a case-fatality rate up to 30 times that of influenza and infects healthcare workers at a significantly higher rate.[3,6,7] Moreover, the concurrence of epidemics appears imminent as the considerable COVID-19 incidence continues and even a moderate influenza season would result in over 35 million cases and 30,000 deaths.[5,6] To help curb this dilemma, front-line providers need the ability to rapidly and accurately triage these patients.

One approach to quickly classifying patients as COVID-19 positive or negative could be through machine learning algorithms. While the use of machine learning has been applied to contact tracing and forecasting during the COVID-19 epidemic [8], it has only limitedly been explored as a means for accurately predicting COVID-19 infection on clinical presentation. With just a few important parameters clinicians can diagnose the patients well before a laboratory diagnosis. Preliminary work has shown the utility of machine and deep learning algorithms in predicting COVID-19 for patient features [9-11] and on CT examination [12,13], but there remains a paucity in research showing the capacity of machine learning algorithms in differentiating between COVID-19 and influenza patients.

Vital signs are critical piece of information used in the initial triage of patients with

COVID-19 and/or influenza by care coordinators and health-care responders in community

urgent care centers or emergency rooms. It is becoming clearer that patient vital signs may

present uniquely in SARS-CoV 2 infection [9], likely as a result of alterations in gas exchange and

microvascular changes [14]. In the present investigation, we therefore explored the use of machine

learning models to differentiate between SARS-CoV 2 and influenza infection using basic office-

based clinical variables. The use of simple ML-based classification may have utility for the rapid

identification, triage, and treatment of COVID-19 and influenza positive patients by front-line

healthcare workers, which is especially relevant as the influenza season approaches.

Results

WVU Study Cohort

Baseline Characteristics

The patient cohort included 3883 patients (mean age 52 ± 24 years, 48% males, and 89%

White/Caucasian) of whom 747 (19%) tested positive for SARSCoV-2 (COVID-19 positive

cohort), 1913 (49%) tested negative for SARSCoV-2 (COVID-19 negative cohort), and 1223

(31%) had influenza (Table 1). The majority of the COVID-19 positive and negative patients

were older; whereas the influenza cohort was younger (P<0.001). There was higher prevalence

of Black/African Americans in the influenza cohort in comparison with other cohorts. COVID-

19 positive patients were more obese (p<0.001). They also had higher mean temperature, systolic

and diastolic blood pressures than the other two cohorts (p<0.001 for all variables). While the

Influenza cohort had higher mean body temperature, heart rate and oxygen saturations than

COVID-19-positive and -negative patients (p<0.001). Patients in the COVID-19-positive and

influenza groups had a higher respiratory rate than the COVID-19-negative group (Table 1).

Outcomes

The overall mortality for the cohort was 6.7%. The crude case fatality rate was 6.8% in

the COVID-19-positive and 4.2% in influenza groups, with a 9.5% case fatality rate in the

COVID-19 negative group (p<0.001). The COVID-19-positive patients had more than a 3-fold

higher rate for ICU admissions than patients with influenza (19.0% vs. 5.7%; p<0.001), but the

rate was lower than the COVID-19 negative group (23.2%) (p<0.001). The average age of

patients who died during hospitalizations was significantly higher in COVID-19 positive patients

(75 ± 14 years) compared to the influenza (69 ± 13years) and COVID-19 negative groups (72 ±

14 years) (p=0.02), as presented in the Table 2.

TriNetX Cohort

The external cohort included a total of 15,697 patient encounters from 3.125 patients with

body temperature information available (Supplementary Table 2). This subgroup of the external

cohort included 6,613 encounters from 1,057 COVID-positive patients and 9,087 encounters

from 2,068 influenza patients. The COVID-19-positive group was predominantly male (54%),

while the influenza group involved more female (53%) patients. The COVID-19-positive group

included more Black/African-American (47%) patients, while the influenza cohort consisted of

more White/Caucasian (52%) patients. The vital signs for mean temperature, heart rate,

respiratory rate, and diastolic blood pressure showed a statistical difference between patients

with COVID-19 and those with influenza (p <0.0001).

COVID-19 Versus Influenza Infection Prediction at the ED or Hospitalization.

In this study we explored the value of demographics, vitals and symptomatic features, which are readily available to providers, in an effort to develop supervised machine learning classifiers that can predict patients who are either COVID-19 positive or negative, while further distinguishing influenza from COVID-19 infection. The WVU hospitalized patient cohort was randomly divided into a training (80%) and testing set (20%) to develop four different contexts specific XGBoost predictive models. We assessed receiver operator characteristic (ROC) area under the curve (AUC) plots, precision, recall and other threshold evaluation metrics to select the best performing model in each case (Tables 3, 4 & S3).

Panel A and B in Figure 1 shows the ROC curves for the prediction of influenza from COVID-19 positive encounters and from those who are either COVID-19 positive or negative obtained using the holdout test set. We present four unique models that can be used as a framework to aid in the delineation between influenza and COVID-19 in the clinical setting. The first model provided stratification of patients as either influenza or COVID-19 positive, highlighted by a ROC AUC 98.8%, accuracy of 95%, sensitivity 94%, and specificity 95% at identifying COVID-19-positive patients (Table 3). The second model distinguished influenza patients from all other patients, irrespective of a patient's COVID-19 test, revealing an ROC AUC of 98.7%, accuracy of 94%, sensitivity of 93%, and specificity of 94% (Figure 1, Panel B). The third model distinguishes between COVID-19 positive and negative patients, with a ROC AUC of 97.2%, accuracy of 92%, sensitivity of 85%, and specificity of 95% (Figure 2, Panel A and Table 3). The Precision-Recall AUC was 94% for predicting COVID-19 positive versus negative patients (Figure S2).

The fourth model employed a multi-class XGBoost framework trained to distinguish

between all three different types of patients had an ROC AUC of 98% and achieved 91%

precision at identifying patients that were positive for influenza with 91% recall, and 95%

precision at identifying those patients that tested negative for COVID-19 with a 88% recall.

While the highest specificity with precision was achieved when identifying COVID-19 positive

patients, the recall of 75% was significantly lower compared to other classes (91% for influenza

and 88% for COVID-19 negative patients). Average precision of the overall model was 91%,

accuracy was 90% and macro-average of ROC AUC was 97.6% (Figure 2 and Table S3).

Importance of Various Features

We use the Shapley Additive Explanations (SHAP) method [15,16], specifically, using the

Tree Explainer method, to describe our XGBoost models.

SHAP Importance

SHAP is a model-agnostic interpretability method that aids in analyzing feature

importance based on their impact on the model's output. The additive importance of each feature

for the model is calculated over all possible orderings of features. Positive SHAP values indicate

a positive impact on the model's output, while negative values indicate negative impact on the

model's output. The most important features that identify patients with positive influenza

infection from others that are presented to ED included features such as age, body temperature,

body surface area (BSA) and heart rate (Figure 3A and B). Encounter-related features such as the

month of encounter along with reason for visit and encounter type also contributed to the most-

informative variables for predicting influenza compared to COVID-19 positive patients or

influenza vs all other patients (Figure 3). On the contrary, in the case of the COVID-19-positive

vs COVID-19 negative model, two vital signs i.e., body temperature and SPO_2 were amongst the

highest-ranking features. Age, BMI, diastolic blood pressure and encounter-related variables

such as reason for visit and month of encounter were additionally amongst the variables most

informative to model predictions. A similar trend of feature importance was also reflected in the

SHAP summary plot of the three-way multi-class classifier (Figure S1). Vital signs played a

more significant role in distinguishing between influenza and COVID-19 positive encounters

through parameters such as body temperature, heart rate and blood pressure.

From the SHAP summary plots (Figure 3 & S1), it is evident that the models captured

some important features and patterns that aid in correctly predicting Influenza and COVID-19-

positive encounters. These plots highlighted that patient encounters predicted to be COVID-19

positive are, on average, more likely to have lower heart rate, higher respiratory rate and lower

oxygen saturation. Lower blood oxygen saturation is known to be prevalent among COVID-19

patients and was identified by our machine learning models as an important feature for ,

validating the clinical appropriateness of our model design.

Model Interpretability

The SHAP force plots shown in Figures 4 & 5 aim to offer explanations for individual

predictions made by our models. The two plots generated for the COVID-19-positive vs

influenza classifier are shown in Figure 4. Panel A shows an encounter correctly classified as

influenza, with the month (during the time course of the traditional influenza season), BSA and

age (younger patient) values affecting the model output most. The effect of these features was

enough to prevent misclassification due to lower heart rate and SBP values. Panel B explains an

encounter correctly classified as COVID-19. While the encounter occurred in month 3, which

overlaps with the influenza season, the combined effect of higher age, low heart rate, BSA and

higher temperature pushes the prediction towards COVID-19, counteracting the effect of month

and encounter type.

Similarly, a second set of plots were generated for the COVID-19 positive vs negative

classifier (Figure 5). In these plots, Panel A shows an encounter correctly classified as COVID-

19 negative while Panel B shows an encounter classified correctly as COVID-19 positive. We

see in the former that the temperature, reason for visit, lower age and higher value of SPO_2 push

the prediction towards COVID-19 negative. In the latter, we see that the effect of temperature,

low SPO_2 value and higher age together counter the effect of the higher heart rate and normal

respiratory rate, to correctly classify the example as COVID-19 positive. With these

interpretability methods we are able to clearly determine the reasons for the model's output and

ensure they can be scrutinized. The insights obtained further corroborate with patterns often

observed in COVID-19 patients.

Impact of Vitals on Model Performance

Stepwise removal of vitals based on feature importance.

Each feature's importance to the construction of the machine learning model was assessed

through individually removing each vital sign parameter in the internal validation set. Stepwise

removal of vitals in the order of their importance of contribution to the multi-class classifier

(Figure S1) led to decrease in the performance of the model (Figure S3A). Removal of body

temperature significantly decreased models' performance to an accuracy of 74% and F1 score of

68% compared to the initial performance 90% and 89%, respectively. However, subsequent

removal of other vital signs, including heart rate did not affect model performance drastically.

Inclusion of only one vital sign at a time.

We also assessed how well the model performs given only one vital is present at a time in

the Internal test set. More specifically, when considering the importance of a given vital sign, all

other features related to vitals are removed from the internal test set. However, the demographics

and other information was not ablated. Figure S3B shows the models performance in terms of F1

score or statistic by only including one vital at a time. The higher the performance, the more

useful the vital sign is in helping the model to discriminate between COVID-19 and influenza

encounters. With the comparison of both multi-class classifier and COVID-19 positive vs

negative classifier performances, it is evident that body temperature has the greatest impact

among all vital signs considered. In addition to body temperature, heart rate was also seen to

contribute to the performance of COVID-19 positive vs negative model.

Taken together, these results suggest that of all the vital signs, body temperature,

followed by heart rate and SPO_2 could impact the predictive models' performance in

discriminating between influenza, COVID-19 positive and negative patient encounters.

External Validation

To further assess the generalizability of the predictive models and confirm the stability of

the model features at identifying patients positive for COVID-19 or influenza, we validated our

models using the TriNetX research network dataset external to WVU Medicine. Patients with

any missing data related to body temperature were excluded from the analysis. The dataset

included 6,613 encounters of COVID-19 patients (n=1,057) and 9,084 encounters related to

influenza patients (n=2,068). The influenza versus COVID-19 model demonstrated ROC AUC

of 92.3% with an accuracy of 85%, and 81% precision at identifying patients that were positive

for COVID-19 with 84% recall (Figure 1A & Table 4). Also, the model to detect patients with

influenza, irrespective of their COVID-19 status, showed similar performance with an AUC

ROC of 92.3% and an accuracy of 80% %, and 99% precision at identifying patients that were

positive for influenza with 68% recall (Figure 1B). This suggests that the developed models are

able to effectively identify patients across multiple TriNetX HCOs with influenza or COVID-19

infections amongst other COVID-19-negative patients presenting at ED and/or admitted to the

hospital.

Further, enforcing no missing values in the case of both heart rate and body temperature,

the two top ranked vital signs (Figure S3), did not result in boosting the performance. On the

contrary, restricting the data to have all vitals present, boosted the performance of ROC AUC to

and accuracy to 88% for the Influenza vs COVID-19 model and ROC AUC to and accuracy to in

the case of Influenza vs Other model (Table S4). These results suggest that while enforcing no

missing values in vitals could support a better overall model performance (i.e., AUC ROC 94.3%

vs 92.3%), missingness in most of the vitals does not seem to limit its applicability and

generalizability.

Discussion

This investigation provides a machine-learning pipeline with a multi-step framework to

differentiate between COVID-19 and influenza. Further, this is the first machine learning model

231 to leverage a patient population that includes both the initial (February-April) and secondary

232 (May-September) surge of SARS-CoV 2 infections in the United States [17]. Our approach can

233 guide future applications, highlighting the importance of developing dynamic models that control

234 for confounding comorbidities, such as influenza, and the ever-evolving infectivity of SARS-

235 CoV 2. Importantly, as influenza season approaches it will be of high priority to establish a

236 reliable process for identifying patients at risk of COVID-19, influenza, or other viral infections

237 to increase the prognostic value of a directed therapy.

238  While the initial presentation of COVID-19 and influenza appear similar, the number,

239 and combination, of signs and symptoms can help provide better stratification. From a symptom

240 standpoint, COVID-19 causes more fatigue, diarrhea, anosmia, acute kidney injury, and

241 pulmonary embolisms, while sputum production and nasal congestion are more specific to

242 influenza [18]. Furthermore, COVID-19 tends to cause worse decompensation. For instance, out of

243 200 cases of either influenza or COVID-19 in a study from France, only COVID-19 resulted in

244 severe respiratory failure requiring intubation[18]. Our evaluation revealed that the month the

245 patient was seen, age, and heart rate were the most important features for predicting a diagnosis

246 of COVID-19 over that of influenza infection. Additionally, body temperature and SPO_2 were

247 two of the most important features that indicated if a patient would be positive or negative for

248 COVID-19, which is likely a result of the underlying pathophysiology of the virus. SARS-CoV 2

249 infection appears to cause more significant endothelial dysfunction and systemic inflammation

250 likely leading to the worse case-fatality rate.[6,19] These differences can be seen histologically as

251 well. Autopsy samples of COVID-19 lung tissue showed severe endothelial injury and

252 widespread thrombosis with microangiopathy [20]. These samples had nine times as much alveolar

capillary microthrombi compared to that of influenza lung tissue and even showed evidence of

new vessel growth through a mechanism of intussusceptive angiogenesis [1,20].

Machine learning algorithms can provide distinct advantages in the classification of

positive COVID-19 cases as the virus, and the demographic it infects, continues to evolve. The

West Virginia University (WVU) cohort consists of a fairly homogenous population, with 89%

of the population identifying as White/Caucasian and only 5% as Black/African American.

While our machine learning models were built around the WVU cohort, they demonstrate robust

performance even on more racially/ethnically diverse populations, such as in the TriNetX

dataset, when predicting patients who have influenza or COVID-19 (ROC AUC = 94.3%) and

influenza only (ROC AUC = 96.2%). The generalizability of our model may suggest that

features that define SARS-CoV 2 infection (e.g., age, heart rate, body temperature, SPO_2) could

represent similarities in clinical presentation, regardless of a patient's race/ethnicity. Further

understanding the socioeconomic [21,22] and physiological [23,24] differences in minority populations

will be important in determining why COVID-19 disproportionately affects these populations

and how machine learning models can more accurately model heterogeneous populations.

Patient information provided in the WVU and TriNetX datasets consists of both the

initial rise in cases in the United States (February-April) as well as a secondary surge (May-

September). The second surge of infections shifted demographically from a predominately older

population to one with the highest prevalence between ages 20-29, with an increased rate of mild

to asymptomatic presentations [25]. Additionally, SARS-CoV 2 is an RNA virus with the capacity

to mutate. Sequencing studies have already identified a variety of genetic variants, with most

mutations currently having no clear association with a positive or negative selective virulence [26].

Though, some mutations, such as D614G, are suggested to increase infectivity of SARS-CoV 2

and outcompete other strains in the environment [27]. Regardless, in our current approach, applying

machine learning over the continuum of the COVID-19 epidemic provides distinct advantages in

producing a generalizable model for continued use, which may not be captured in models

generated on earlier datasets.

The current study provides robust ROC AUC prediction of patients with COVID-19

(98.3%), without COVID-19 (97.4%), and those with influenza (97.1%) in our multi-class

model. While only demographic information and vital signs were applied to our models, overall

prediction could likely improve with the addition of other features including biochemical,

metabolic, and molecular markers, as well as imaging modalities such as X-ray and CT. The

addition of these features could likely improve diagnostic accuracy and should be tested in future

studies delineating between COVID-19 and influenza. Additionally, the current investigation

involves influenza and COVID-19 data from non-overlapping periods (i.e., influenza from winter

2019 and COVID-19 from spring/summer/fall 2020). Although some of the machine learning

models rely on time of presentation for prediction, we anticipate that the four-model framework

provided in the study will sufficiently stratify patients even when influenza season and the

COVID-19 epidemic overlap. This is reinforced by the prediction of COVID-19 positive and

negative cases (ROC AUC = 97.2%) in our model, which did not rely on time of presentation as

a variable.

Our study was limited by the classification of patients in the internal (WVU) and external

(TriNetX) datasets. While the WVU cohort includes patients, who have been confirmed to have a

negative SARS-CoV 2 test on presentation, the TriNetX dataset does not have this information.

Both datasets are also unable to capture patients with other respiratory viruses and viral

coinfections; information that could better explain variations in COVID-19 clinical presentation.

Another limitation is the need to continually adjust these models to fit new trends in SARS-CoV

2 spread and infectivity. Our models benefit from the inclusion of data spanning from February

to October, which can better simulate the current COVID-19 epidemic and influenza season but

will still require future iterations and validations to accurately predict SARS-CoV 2 infections.

Further, an understanding of COVID-19 and viral co-infections is needed to appropriately model

the risks of patients presenting with both illnesses [28-30].

Conclusions

Here we highlight how machine learning can effectively classify influenza and COVID-

19 positive cases through vital signs on clinical presentation. This work is the first step in

building a low-cost, robust classification system for the appropriate triage of patients displaying

symptoms of a viral respiratory infection. With these algorithms, the identification of proper

treatment modalities for both COVID-19 and influenza can be made more rapidly, increasing the

effectiveness of patient care.

Outlook

We certainly hope that our current work can aid healthcare workers and clinicians to rapidly

identify, triage, and guide treatment decisions when the two viral infections start cocirculating in

the communities. In addition, Further studies validating the model as we see more coinfection in

an upcoming season can significantly improve the quality of care and proper allocation of

resources during this global pandemic.

Materials and Methods

WVU Internal Cohort Dataset

De-identified clinical and demographics data for all patients presenting to the emergency department and/or admitted at West Virginia University hospitals between January 1st, 2019, and November 4th, 2020, were extracted and provided to us by WVU Clinical and Translational Science Institute (CTSI). The COVID-19 positive dataset includes all patients who had a lab-based diagnostic test positive for SARS-CoV-2 at WVU Medicine between March 1st, 2020, and November 4th, 2020 and had an associated hospital encounter with all vital signs information available. The influenza positive dataset includes a random sample of 1500 patients who had a lab-based diagnostic test that was positive for either Influenza Type A or Influenza Type B at WVU Medicine between January 1st, 2019, and November 3rd, 2020, and had a hospital encounter associated with that positive test. The COVID-19 negative dataset includes a random sample of 2000 patients who had negative test results for SARS-CoV-2 and who never had a positive diagnostic test for SARS-CoV-2 at WVU Medicine between March 1st, 2020, & November 4th, 2020 provided that an associated hospital encounter occurred with that negative test. As our study aims to create a model that can accurately discriminate COVID-19 from influenza patients solely based on the patient's demographic information and vital signs data, patients with any of the vital signs missing during the associated encounters were therefore excluded from the analysis. This resulted in a final WVU cohort that included a total of 747 COVID-19 positive, 1223 influenza and 1913 COVID-19 negative patients (Table 1).

TriNetX External Cohort Dataset

The external validation cohort was obtained from the TriNetX Research network, a cloud-based database resource that provides researchers access to de-identified patient data from networks of healthcare organizations (HCO), mainly from large academic centers and other data providers. The data is directly pulled from electronic medical records and accessible in a de-identified manner. The TriNetX database includes patient-level demographic, vital signs, diagnoses, procedures, medications, laboratory, and genomic data. For this study, we identified COVID-19 and influenza cases using the International Classification of Diseases, 10th revision. We used ICD-10 codes J9.0, J10.0, J09.*, and J10.* for influenza, and U07.1 for COVID-19. Cases from February 1st, 2020, to August 13th, 2020, were queried and extracted. Due to heterogeneity in reporting of COVID-19 testing (i.e., positive vs. negative; normal vs. abnormal), we refrained from selecting the patients based on their testing results and used diagnostic codes instead. Thus, we were only able to extract COVID-19 positive and influenza positive patients for external validation. Further patients at least 18 years or older at the time of diagnosis and their encounters defined as an encounter occurring within 7days from the date of diagnosis were enforced to be included in the final cohort (n=34,670). Enforcing no missing values corresponding to body temperature resulted in a dataset (n=15,697) that had a total of 6,613 (n=1057 patients) and 9084 (n=2068 patients) encounters diagnosed with COVID-19 and Influenza, respectively. Baseline characteristics of the cohort is described in Supplementary Table 2. Since the TriNetX data is de-identified, Institutional Board Review (IRB) oversight is not necessary.

Data Preprocessing & Split

Different clinical variables investigated in this study include (a) vital signs i.e., body temperature, heart rate, breathing/respiratory rate, oxygen saturation or SPO_2 and blood pressure, (b) encounter date/type, (c) reason for visit, and (d) basic demographics information such as Age, Gender, Race, and Ethnicity. Of the features considered, the data elements corresponding to sex and ethnicity were binarized for being "female" and "Hispanic or Latino", respectively. The race feature was further one-hot encoded to three variables i.e., race_White/Caucasian, race_Black/African American and race_Other. Finally, the date of the encounter was converted to represent a numerical value for month, rather than specific day/year to remove the granularity and capture the seasonal effects of influenza.

Predictive Model Development using Extreme Gradient Boosting Trees

Model Training and Testing

XGBoost, a gradient-boosted tree algorithm, was used to develop classifiers to distinguish between patient encounters with confirmed COVID-19 from that of either influenza patient encounters or other unknown viral infections. Separate models were developed to predict confirmed COVID-19 patient encounters post Feb 1, 2020 from either influenza and/or those that tested negative for COVID-19 (i.e., COVID-19 positive vs influenza, COVID-19 positive vs COVID-19 negative, COVID-19 positive vs influenza vs COVID-19 negative), and then an additional model to test influenza infections from others i.e., patients that were either positive or negative to a COVID-19 test (Influenza vs Others). For the purpose of model training and testing, we only consider data from 01-Feb-2020 until 04-Nov-2020 for COVID-19 positive and

negative cohorts and from 01-Jan-2019 to 04-Nov-2020 for the influenza patient cohort. We

partitioned the dataset into training and testing sets, using an 80%–20% split. The holdout test, or

internal validation, set is never seen by the model during training and was used only during

performance evaluation.

Gradient-boosted trees were selected due to their ability to model complex nonlinear

relationships, while robustly handling outliers and missing values. Gradient-boosted trees fuse

the concepts of gradient descent (in the loss function space) and boosting. Simpler tree-based

models are built additively like a boosting ensemble, to fit the gradient of the loss function for

every data point. Only a fraction of the trees fit to the gradient of the loss per data point in the

training set. This is analogous to small steps of gradient descent in the loss function space.

For developing the COVID-19 positive vs negative, Influenza vs Others and COVID-19

vs Influenza XGBoost models, the value of learning rate was set to 0.02 and the total number of

trees was 600. The alpha value was set to 0 and lambda was set to 1, i.e., we use L2

regularization. Further, min_child_weight was set to 1, to allow highly specific patterns to be

learnt as well. To counter the possibility of overfitting, the max_depth parameter of the XGBoost

model was set to 4, as more complex features are learnt with higher depths, leading to poor

performance on the unseen data. We used the gain importance metric to decide node splits for

the tree estimator, and the objective was set to binary logistic regression. The model outputs the

predicted probability, and records whose probability was at least 0.5 were considered as

belonging to the positive class, while others were deemed to belong to the negative class.

Further, the subsample parameter of the XGBoost algorithm represents the ratio of the records to

be sampled before forming a tree and was set to a value of 0.8. Similarly, the colsample_bytree

parameter which determines the fraction of columns to be sampled before every tree formation

was set to 1, meaning all features are used. Only records with all vitals were considered, however

the model does have the ability to make predictions in the absence of certain features. The

compute_sample_weight from the sklearn.utils.class_weight library was employed to ensure that

each training sample is weighted based on its class, to counter imbalance in the dataset.

For the three-class classifier that discriminates between COVID-19-positive, COVID-19-

negative and Influenza encounters, we developed an XGBoost model of 100 trees, with

learning_rate set to 0.3 and max_depth fixed at 6. The objective was set to softprob (uses a

softmax objective function), to perform multi-class classification. Furthermore, the subsample

parameter was set to 1, meaning all samples were used to form trees. No sample weighting was

carried out for this model. All other parameters remained the same as the models discussed

previously.

Model Validation

We also consider an unseen external validation dataset (TriNetX cohort) to evaluate the

performance of the model on data that is completely different from what it is accustomed to

during training. Patient-wise encounters with no missing vitals were enforced to test and evaluate

the performance of the developed models.

Performance Evaluation Metrics

The discriminative ability of each of the models developed in predicting patients with

influenza from COVID-19 positive and /or negative patients as well as those with a positive

COVID-19 test from negative test was evaluated in the hold-out test set and an external

validation test by using receiver operator characteristic (ROC) curve analysis. An area under the

curve (AUC)$>$0.5 indicated better predictive values. The closer the AUC was to 1, the better

the model's performance was. Additionally, "classification accuracy", the total number of true

positive scores i.e. when predicted values are equal to the actual values given by the attribute

positive predictive value (PPV) or "precision" score, "recall" which is the total number of true

positive instances among all the positive instances, and "F1 score" the weighted harmonic mean

of precision and recall along with negative predictive value (NPV) were estimated to evaluate

performance and the overall generalizability of each of the models. Further details on the

calculations of different metrics employed are provided in Supplementary methods.

Statistical analysis

We performed the Shapiro-Wilk test on the entire WVU internal cohort dataset to check

for normalcy of the data. We found that all the variables were normally distributed; therefore, we

used parametric methods for further statistical analysis. Categorical data are presented as counts

(percentages) while continuous data were reported as mean ± standard deviation (SD). To

determine the significance of continuous variables between all three different groups (i.e.,

COVID-19 positive, influenza, and COVID-19 negative) Kruskal-Wallis test with Dunn-

Bonferroni correction test was used. The comparison between two of these three groups

(COVID-19 positive vs negative, COVID-19 positive vs influenza, influenza vs COVID-19

negative) to determine significance was performed using an independent sample t-test. Chi-

square was used for the categorical variable because the expected value for each cell is greater

than 5. All statistical analysis was performed using Medcalc for Windows, version 19.5.3

(MedCalc Software, Ostend, Belgium), and python for windows, version 3.8.3. A statistical

significance level of $p < 0.05$ was used for all the tests performed**.**

Data Availability Statement

459   The data that support the findings of this study are available from WVU CTSI & TriNetX but

460   restrictions apply to the availability of these data, which were used under license for the current

461   study, and so are not publicly available. Data is however available from the authors upon

462   reasonable request and with permission of WVU CTSI & TriNetX.

Code availability

465   The code is made available at https://github.com/ynaveena/COVID-19-vs-Influenza for non-

466   commercial use.

References

469   1   Ackermann, M. *et al.* Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in
470   Covid-19. *N Engl J Med* **383**, 120-128, doi:10.1056/NEJMoa2015432 (2020).
471   2   Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected
472   Pneumonia. *N Engl J Med* **382**, 1199-1207, doi:10.1056/NEJMoa2001316 (2020).
473   3   Zhu, N. *et al.* A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*
474   **382**, 727-733, doi:10.1056/NEJMoa2001017 (2020).
475   4   Lee, Y. H., Hong, C. M., Kim, D. H., Lee, T. H. & Lee, J. Clinical Course of Asymptomatic and Mildly
476   Symptomatic Patients with Coronavirus Disease Admitted to Community Treatment Centers,
477   South Korea. *Emerg Infect Dis* **26**, 2346-2352, doi:10.3201/eid2610.201620 (2020).
478   5   Gostin, L. O. & Salmon, D. A. The Dual Epidemics of COVID-19 and Influenza: Vaccine
479   Acceptance, Coverage, and Mandates. *JAMA* **324**, 335-336, doi:10.1001/jama.2020.10802
480   (2020).
481   6   Solomon, D. A., Sherman, A. C. & Kanjilal, S. Influenza in the COVID-19 Era. *JAMA*,
482   doi:10.1001/jama.2020.14661 (2020).
483   7   Zayet, S. *et al.* Clinical features of COVID-19 and influenza: a comparative study on Nord
484   Franche-Comte cluster. *Microbes Infect*, doi:10.1016/j.micinf.2020.05.016 (2020).

8   Lalmuanawma, S., Hussain, J. & Chhakchhuak, L. Applications of machine learning and artificial
intelligence for Covid-19 (SARS-CoV-2) pandemic: A review. *Chaos Solitons Fractals* **139**, 110059,
doi:10.1016/j.chaos.2020.110059 (2020).

9   Soltan, A. A. S. *et al.* Artificial intelligence driven assessment of routinely collected healthcare
data is an effective screening test for COVID-19 in patients presenting to hospital.
doi:https://doi.org/10.1101/2020.07.07.20148361; (2020).

10   Sun, L. *et al.* Combination of four clinical indicators predicts the severe/critical symptom of
patients infected COVID-19. *J Clin Virol* **128**, 104431, doi:10.1016/j.jcv.2020.104431 (2020).

11   Wu, J. *et al.* Rapid and accurate identification of COVID-19 infection through machine learning
based on clinical available blood test results. *medRxiv*,
doi:https://doi.org/10.1101/2020.04.02.20051136; (2020).

12   Ardakani, A. A., Kanafi, A. R., Acharya, U. R., Khadem, N. & Mohammadi, A. Application of deep
learning technique to manage COVID-19 in routine clinical practice using CT images: Results of
10 convolutional neural networks. *Comput Biol Med* **121**, 103795,
doi:10.1016/j.compbiomed.2020.103795 (2020).

13   Ozturk, T. *et al.* Automated detection of COVID-19 cases using deep neural networks with X-ray
images. *Comput Biol Med* **121**, 103792, doi:10.1016/j.compbiomed.2020.103792 (2020).

14   Diehl, J. L. *et al.* Respiratory mechanics and gas exchanges in the early course of COVID-19 ARDS:
a hypothesis-generating study. *Ann Intensive Care* **10**, 95, doi:10.1186/s13613-020-00716-1
(2020).

15   Lundberg, S. M., Lee Su-In in *31st Conference on Neural Information Processing Systems (NIPS*
2017), Long Beach, CA, USA.

16   Lundberg, S. M. *et al.* From Local Explanations to Global Understanding with Explainable AI for
Trees. *Nat Mach Intell* **2**, 56-67, doi:10.1038/s42256-019-0138-9 (2020).

17   Roser, M., Ritchie, H., Ortiz-Ospina, E. & Hasell, J.   (Published online at OurWorldInData.org,
2020).

18   Faury, H. *et al.* Medical features of COVID-19 and influenza infection: A comparative study in
Paris, France. *J Infect*, doi:10.1016/j.jinf.2020.08.017 (2020).

19   Vardeny, O., Madjid, M. & Solomon, S. D. Applying the Lessons of Influenza to COVID-19 During
a Time of Uncertainty. *Circulation* **141**, 1667-1669, doi:10.1161/CIRCULATIONAHA.120.046837
(2020).

20   Calabrese, F. *et al.* Pulmonary pathology and COVID-19: lessons from autopsy. The experience of
European Pulmonary Pathologists. *Virchows Arch* **477**, 359-372, doi:10.1007/s00428-020-02886-
6 (2020).

21   Chowkwanyun, M. & Reed, A. L., Jr. Racial Health Disparities and Covid-19 - Caution and
Context. *N Engl J Med* **383**, 201-203, doi:10.1056/NEJMp2012910 (2020).

22   Selden, T. M. & Berdahl, T. A. COVID-19 And Racial/Ethnic Disparities In Health Risk,
Employment, And Household Composition. *Health Aff (Millwood)* **39**, 1624-1632,
doi:10.1377/hlthaff.2020.00897 (2020).

23   Fei, K. *et al.* Racial and Ethnic Subgroup Disparities in Hypertension Prevalence, New York City
Health and Nutrition Examination Survey, 2013-2014. *Prev Chronic Dis* **14**, E33,
doi:10.5888/pcd14.160478 (2017).

24   Forde, A. T. *et al.* Discrimination and Hypertension Risk Among African Americans in the Jackson
Heart Study. *Hypertension* **76**, 715-723, doi:10.1161/HYPERTENSIONAHA.119.14492 (2020).

25   Boehmer, T. K. *et al.* Changing Age Distribution of the COVID-19 Pandemic - United States, May-
August 2020. *MMWR Morb Mortal Wkly Rep* **69**, 1404-1409, doi:10.15585/mmwr.mm6939e1
(2020).

26 Day, T., Gandon, S., Lion, S. & Otto, S. P. On the evolutionary epidemiology of SARS-CoV-2. *Curr*
Biol **30**, R849-R857, doi:10.1016/j.cub.2020.06.031 (2020).
27 Zhang, L. *et al*. The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and
increases infectivity. *bioRxiv*, doi:10.1101/2020.06.12.148726 (2020).
28 Ding, Q., Lu, P., Fan, Y., Xia, Y. & Liu, M. The clinical characteristics of pneumonia patients
coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. *J Med Virol*,
doi:10.1002/jmv.25781 (2020).
29 Miatech, J. L., Tarte, N. N., Katragadda, S., Polman, J. & Robichaux, S. B. A case series of
coinfection with SARS-CoV-2 and influenza virus in Louisiana. *Respir Med Case Rep* **31**, 101214,
doi:10.1016/j.rmcr.2020.101214 (2020).
30 Zhou, X. *et al*. The Outbreak of Coronavirus Disease 2019 Interfered with Influenza in Wuhan
SSRN, doi:http://dx.doi.org/10.2139/ssrn.3555239 (2020).

Acknowledgements

The authors acknowledge Matthew Armistead, Emily Morgan, Maryam Khodaverdi, and Wes

Kimble for their support with data collection and providing de-identified datasets.

Funding Information: This work is supported in part by funds from the National Science

Foundation (NSF: # 1920920) National Institute of General Medical Sciences of the National

Institutes of Health under (NIH: #5U54GM104942-04). The content is solely the responsibility

of the authors and does not necessarily represent the official views of the National Institutes of

Health or National Science Foundation.

Author Contributions

P.P.S and NY envisioned and designed the projects. NY, N.H.K, AR, and SS performed machine

learning modeling and analysis. P.P.S., Q.A.H, BP, and PF was involved with clinical

interpretation of the findings and writing as well as editing the manuscript. H.B.P and S.S.

performed the statistical analysis. All the authors have significantly been involved in the drafting

of the manuscript or revising it critically for important intellectual content.

Competing Interests

The authors declare the following competing interests. Dr. Sengupta is a consultant for

HeartSciences, Kencor Health and Ultromics. The remaining authors declare no competing

interests.

Figures.

Figure 1. Receiver Operating Characteristic Curves showing the predictive performance of the

(a) influenza versus COVID-19-positive model and (b) Influenza versus Other prediction models

on the internal test and external validation datasets.

572
573

Figure 2. Receiver Operating Characteristic Curves showing the predictive performance of the

(a) COVID-19-positive versus COVID-19-negative, and (b) Influenza versus Other prediction

models on the internal validation test.

Figure 3. SHAP summary plot depicting the relative importance, impact and contribution of

different features on the output of (a) Influenza vs COVID-19-positive, (b) Influenza vs Other

and (c) COVID-19-positive vs COVID-19-negative predictive models.

Figure 4. SHAP explanations for observations from (a) Influenza A/B and (b) COVID-19-positive predictions. The underlying model

is XGBoost. Features that are contributing to a higher and lower probability are shown in red and blue, respectively along with the size

of each feature's contribution to the model output.

a. Influenza

b. COVID-19-positive

587   **Figure 5.** SHAP force plots of two patient encounters with (a) COVID-19-positive and (b) COVID-19-negative predictions. Features

588   that are contributing to a higher and lower probability are shown in red and blue, respectively along with the size of each feature's

589   contribution to the model output.

591　Tables.

TABLE 1. Demographics of WVU Patients (included COVID-19-positive, COVID-19-negative and Influenza cohort)

	Overall	COVID-19-positive	Influenza	COVID-19-negative	p value
N	3883	747	1223	1913	
Overall Age, in years	52 ± 24	$55 \pm 22^{*}$	$41 \pm 24^{\dagger}$	57 ± 23	$< 0.001^{\ddagger}$
Age by groups					$< 0.001^{\S}$
Kids & Teens (0-20)	520	63 (8.4)	319 (26.1)	138 (7.2)	
Adults (21-44)	940	171 (22.9)	349 (28.5)	420 (22.0)	
Older Adults (45-64)	1005	216 (28.9)	282 (23.1)	507 (26.5)	
Seniors (65 or older)	1418	297 (39.8)	273 (22.3)	848 (44.3)	
Male, n(%)	1876	375 (50.2)	585 (47.8)	916 (47.9)	0.51
Race					$< 0.001^{\S}$
White/Caucasian, n(%)	3455	641 (85.8)	1037 (84.8)	1777 (92.9)	
Black/African-American,n(%)	203	48 (6.43)	95 (7.8)	60 (3.1)	
Other, n(%)	225	58 (7.8)	91 (7.4)	76 (4.0)	
Ethnicity					$< 0.001^{\S}$
Hispanic/Latino, n(%)	94	34 (4.6)	43 (3.5)	17 (0.9)	
Other, n(%)	3789	713 (95.5)	1180 (96.5)	1896 (99.1)	
Body Mass Index, kg/m^2	30.0 ± 9.4	$31.6 \pm 8.8^{*\dagger}$	29.7 ± 9.5	29.6 ± 9.5	$< 0.001^{\ddagger}$
Vitals, (mean±SD)					
Temperature in ºF,	98.3 ± 1.1	$98.3 \pm 1.1^{*\dagger}$	$99.0 \pm 1.3^{\dagger}$	98.0 ± 0.8	$< 0.001^{\ddagger}$
Systolic blood pressure, mmHg	126 ± 20	$127 \pm 19^{*}$	$124 \pm 19^{\dagger}$	126 ± 20	$0.004^{\ddagger}$
Diastolic blood pressure, mmHg	73 ± 13	$75 \pm 13^{*\dagger}$	72 ± 12	73 ± 13	$< 0.001^{\ddagger}$
Heart rate, beats per minutes	87 ± 18	$83 \pm 16^{*}$	$94 \pm 20^{\dagger}$	83 ± 17	$< 0.001^{\ddagger}$
Oxygen Saturation (SpO2), %	96 ± 4	$96 \pm 4^{*\dagger}$	$97 \pm 3^{\dagger}$	96 ± 4	$< 0.001^{\ddagger}$
Respiratory rate	19 ± 4	$19 \pm 4^{*}$	$19 \pm 3^{\dagger}$	18 ± 5	$< 0.001^{\ddagger}$

Values reported are counts (%) or mean ± standard deviation.
∗ p < 0.05 compared with the influenza group.
† p < 0.05 compared with the COVID-19-negative group.
‡ p < 0.05 using Kruskal Wallis test with Dunn-Bonferroni correction.
§ p < 0.05 using Chi-square test.

TABLE 2. Outcomes of WVU Patients presented at ED or admitted to WVU hospitals and

tested positive for COVID-19, positive for Influenza A/B or negative for COVID-19.

	Overall	COVID-19-positive	Influenza	COVID-19-negative	p value
N	3883	747	1223	1913	
No. of ICU admissions, n (%)	655 (16.8)	142 (19.0)	70 (5.7)	443 (23.2)	$< 0.001^{\S}$
Patient needing Ventilator, n (%)	264 (6.8)	43 (5.8)	39 (3.2)	182 (9.5)	$< 0.001^{\S}$
No. of deaths, n(%)	261 (6.7)	51 (6.8)	51(4.2)	159 (8.3)	$< 0.001^{\S}$
Age (in years) at death, mean±SD	72 ± 14	75 ± 14[*]	69 ± 13	72 ± 14	$0.02^{\ddagger}$

Values reported are counts (%) or mean ± standard deviation.
∗ p < 0.05 compared with the influenza group.
‡ p < 0.05 using Kruskal Wallis test with Dunn-Bonferroni correction.
§ p < 0.05 using Chi-square test.

600 **TABLE 3.** Performance metrics of different XGBoost models for predicting the given record as
601 COVID-19-positive or influenza when tested on Internal validation or test set.

Performance Measure	Influenza vs COVID-19-positive	Influenza vs Others	Covid-19-positive vs COVID-19-negative
AUC	0.988	0.987	0.972
Accuracy	0.949	0.937	0.922
F1 Score	0.929	0.909	0.861
Sensitivity (Recall)	0.938	0.931	0.849
Specificity	0.954	0.940	0.951
PPV (Precision)	0.920	0.887	0.873
NPV	0.965	0.964	0.941
FPR	0.046	0.060	0.049
FDR	0.081	0.113	0.127
FNR	0.062	0.069	0.151

604 **TABLE 4.** Performance of Influenza versus COVID-19-positive and Influenza versus Others

605 (COVID-19-positive/-negative) classification models on the external validation cohort.

Performance Measure	Influenza vs COVID-19-positive	Influenza vs Others
AUC	0.923	0.923
Accuracy	0.852	0.801
F1 Score	0.827	0.807
Sensitivity (Recall)	0.842	0.682
Specificity	0.860	0.989
PPV (Precision)	0.814	0.990
NPV	0.882	0.664
FPR	0.141	0.011
FDR	0.187	0.010
FNR	0.158	0.318

606